Modica, Roberta
 Distribuzione geografica
Continente #
AS - Asia 3.670
EU - Europa 2.224
NA - Nord America 1.906
SA - Sud America 444
AF - Africa 86
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 8.338
Nazione #
SG - Singapore 1.935
US - Stati Uniti d'America 1.819
RU - Federazione Russa 1.248
CN - Cina 980
BR - Brasile 351
IT - Italia 323
HK - Hong Kong 291
VN - Vietnam 198
DE - Germania 170
NL - Olanda 92
KR - Corea 89
GB - Regno Unito 77
FI - Finlandia 74
FR - Francia 71
IN - India 63
CA - Canada 47
AR - Argentina 41
CI - Costa d'Avorio 38
SE - Svezia 32
UA - Ucraina 29
MX - Messico 27
ZA - Sudafrica 24
PL - Polonia 23
ES - Italia 19
BD - Bangladesh 16
CO - Colombia 16
AT - Austria 15
ID - Indonesia 15
IE - Irlanda 15
JP - Giappone 15
EC - Ecuador 14
TR - Turchia 10
IQ - Iraq 9
AZ - Azerbaigian 7
CZ - Repubblica Ceca 7
UZ - Uzbekistan 7
BE - Belgio 6
LT - Lituania 6
MA - Marocco 6
CL - Cile 5
VE - Venezuela 5
AU - Australia 4
MY - Malesia 4
PE - Perù 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
HR - Croazia 3
JO - Giordania 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
PK - Pakistan 3
PY - Paraguay 3
UY - Uruguay 3
BO - Bolivia 2
BW - Botswana 2
BY - Bielorussia 2
CR - Costa Rica 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GI - Gibilterra 2
LY - Libia 2
MD - Moldavia 2
MZ - Mozambico 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
SA - Arabia Saudita 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CH - Svizzera 1
CM - Camerun 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
NI - Nicaragua 1
PW - Palau 1
RS - Serbia 1
RW - Ruanda 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TL - Timor Orientale 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 8.338
Città #
Singapore 1.016
Hefei 490
Moscow 337
Hong Kong 291
Beijing 250
Ashburn 238
Chandler 185
Santa Clara 156
Seoul 88
Los Angeles 86
Naples 86
Amsterdam 73
Ho Chi Minh City 71
Munich 59
San Jose 59
Hanoi 45
Redondo Beach 43
Buffalo 37
Helsinki 35
Seattle 35
São Paulo 34
Kochi 32
New York 31
The Dalles 31
Frankfurt am Main 29
Düsseldorf 24
Turku 24
Boston 23
Milan 23
Millbury 23
Orem 21
Dallas 20
Des Moines 20
Rome 20
London 19
Napoli 19
Brooklyn 17
Jacksonville 17
Chicago 16
Mexico City 16
Rio de Janeiro 16
Warsaw 16
Denver 15
Falkenstein 15
Lawrence 15
Nanjing 15
Ottawa 15
Chennai 14
Houston 14
Stockholm 14
Poplar 13
Princeton 13
Tokyo 13
Dong Ket 12
Nuremberg 12
Washington 12
Wilmington 12
Johannesburg 11
Toronto 11
Lappeenranta 10
Phoenix 10
Portici 10
Portsmouth 10
Roubaix 10
San Francisco 9
Atlanta 8
Brasília 8
Council Bluffs 8
Kronberg 8
Afragola 7
Bexley 7
Biên Hòa 7
Buenos Aires 7
Campinas 7
Montreal 7
Nanchang 7
Porto Alegre 7
Vienna 7
Baku 6
Brussels 6
Dhaka 6
Guayaquil 6
Manchester 6
Phủ Lý 6
Salt Lake City 6
Caxias do Sul 5
Da Nang 5
Dublin 5
Haiphong 5
Hải Dương 5
Lauterbourg 5
Mumbai 5
Ninh Bình 5
Paris 5
Rochdale 5
Tashkent 5
Uberlândia 5
Ankara 4
Bari 4
Belo Horizonte 4
Totale 4.665
Nome #
GLP-1: benefits beyond pancreas. 132
Emerging therapies in pheochromocytoma and paraganglioma: Immune checkpoint inhibitors in the starting blocks 131
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. 130
Hepatic arterial embolization in patients with neuroendocrine tumors. 129
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 125
Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis 121
Quality of life in patients with neuroendocrine neoplasms: The role of severity, clinical heterogeneity and resilience 121
A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy 120
Pituitary function and morphology in Fabry disease. 120
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 119
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 115
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 115
Bone metastases in neuroendocrine neoplasms: From pathogenesis to clinical management 114
Diagnosis of Flier’s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature 113
A rare rarity: Neuroendocrine tumor of the esophagus 111
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 110
Open issues on G3 neuroendocrine neoplasms: Back to the future 109
Nutrition and neuroendocrine tumors: An update of the literature. 108
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm 107
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 105
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies (Oct, 10.1007/s40618-022-01905-4, 2022) 103
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors 102
Neuroendocrine Neoplasms 100
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 99
An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma 99
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives 96
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature 96
Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors 96
The safety of available treatments options for neuroendocrine tumors 96
Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences 96
Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms 95
Characterization of Atypical Pheochromocytomas with Correlative MRI and Planar/Hybrid Radionuclide Imaging: A Preliminary Study 95
Interventional cytopathologist can successfully combine ultrasonographical and microscopic skills to narrow the differential diagnosis in fine‐needle aspiration of neck paraganglioma 92
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons 91
Risk factors for gastroenteropancreatic neuroendocrine neoplasms ({GEP}-{NENs}): a three-centric case{\textendash}control study 91
Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study 91
ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence 89
Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study 89
Nonconventional Doses of Somatostatin Analogs in Patients with Progressing Well-Differentiated Neuroendocrine Tumor 88
Role of Metformin on Recurrence-Free Survival in Neuroendocrine Tumors 88
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 88
Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1 88
Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target 88
Prognostic significance of laterality in lung neuroendocrine tumors 87
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus 87
Parathyroid diseases and metabolic syndrome 86
Role of Bone Metastases in Lung Neuroendocrine Neoplasms: Clinical Presentation, Treatment and Impact on Prognosis 86
Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune–Inflammation Index (SII) as Potential Biomarkers in Patients with Sporadic Medullary Thyroid Cancer (MTC) 86
Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery 86
MR imaging characterization of pheochromocytoma: a comparison between typical and atypical tumor lesions 85
Sunitinib nei feocromocitomi e paragangliomi 84
PRRT: identikit of the perfect patient 83
Neuroendocrine Tumors and Immune System 83
Carcinoide timico in paziente affetta da sindrome da neoplasie endocrine multiple di tipo 1 (MEN1): ruolo dello screening radiologico e medico-nucleare 82
Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors 82
Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference 81
Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence 80
Selpercatinib e carcinoma midollare della tiroide 80
Erratum to: GLP-1: Benefits beyond pancreas 80
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms 79
Gestione integrata del tumore della prostata: il ruolo dell’endocrinologo 78
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 78
Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship 77
Nuove strategie terapeutiche per il trattamento dei NET 77
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 75
Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms 75
Corrigendum to: Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience (vol 106, pg e316, 2020) 74
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 73
Endocrine Pathology 73
Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience 71
Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family 71
Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature 70
Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors 70
Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection 69
What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature 68
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 67
Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? 67
Cardiac mechanical synchrony couples with myocardial sympathetic innervation. A retrospective study with novel echocardiographic assessment in patients with 123I-mIBG imaging 66
Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: results of a multicenter study and comparison between different assays 65
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 63
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus 62
Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers 60
Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy 60
Editorial: Neuroendocrine tumors: the road to precision medicine 59
Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1) 59
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 59
Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) in Sicily: Confirmation that R203X is the peculiar AIRE gene mutation 58
Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials? 57
Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors 54
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? 52
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial 49
Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia 48
Carcinoma showing thymus-like differentiation (CASTLE): a case report 47
Thyroid transcription factor‐1 expression in lung neuroendocrine tumours: a gender-related biomarker? 46
Telling science and Innovation. Rare plat net 45
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists 45
Gender perspective in Lung Neuroendocrine Tumors: a critical review 44
Authorship of Italian medical literature on neuroendocrine neoplasms: any gender gap? 44
Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead 44
Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms 38
Totale 8.385
Categoria #
all - tutte 27.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.629


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202138 0 0 0 0 0 0 9 1 7 2 6 13
2021/2022215 2 0 25 3 5 14 1 6 17 16 64 62
2022/2023494 31 57 14 39 51 41 54 33 50 81 41 2
2023/2024515 20 66 53 48 40 67 17 84 3 16 69 32
2024/20253.037 108 83 25 34 104 213 327 240 173 320 1.126 284
2025/20263.996 606 761 672 642 1.031 198 86 0 0 0 0 0
Totale 8.492